Fig. 2. Inhibition of VACV replication by trifluridine and Adefovir dipivoxil (ADP) by plaque assay.

(A) Structures of trifluridine (4), adefovir dipivoxil (ADP, 5), and AraC (6). (B) HFFs were infected with VACV at an MOI of 0.01 treated with indicated compounds at 10 μM for 48 h. Viral yields were titrated using a plaque assay on BS-C-1 cells. (C) HFF cell viabilities were measured 48 h after the cells were treated with indicated compounds at 10 μM. At least three repeats were performed for all assays. **0.001<p ≤ 0.01, ns, not significant.